Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUSNASDAQ:HCMNASDAQ:IMVTNASDAQ:MLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$3.32+2.6%$3.28$2.71▼$4.73$636.67M1.5996,858 shs393,708 shsHCMHUTCHMED$13.96-1.8%$14.74$11.51▼$21.87$2.43B0.55102,486 shs40,743 shsIMVTImmunovant$14.53+3.6%$16.48$12.72▼$34.47$2.47B0.751.21 million shs449,134 shsMLTXMoonLake Immunotherapeutics$40.65+5.7%$38.43$31.42▼$58.26$2.60B1.31354,546 shs96,884 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma0.00%-10.03%+2.87%-3.00%+12.15%HCMHUTCHMED0.00%-4.93%+3.94%+6.26%-34.44%IMVTImmunovant0.00%-11.27%-4.50%-28.18%-52.30%MLTXMoonLake Immunotherapeutics0.00%-9.10%+10.23%-12.71%-5.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABUSArbutus Biopharma2.0978 of 5 stars3.50.00.00.03.32.50.6HCMHUTCHMED2.0545 of 5 stars3.02.00.00.02.60.01.9IMVTImmunovant2.2898 of 5 stars4.50.00.00.03.21.70.0MLTXMoonLake Immunotherapeutics1.8919 of 5 stars3.50.00.00.03.72.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 3.00Buy$5.5065.91% UpsideHCMHUTCHMED 2.00Hold$19.0036.14% UpsideIMVTImmunovant 2.90Moderate Buy$38.33163.88% UpsideMLTXMoonLake Immunotherapeutics 3.00Buy$80.5098.03% UpsideCurrent Analyst Ratings BreakdownLatest ABUS, MLTX, HCM, and IMVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.004/22/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$38.00 ➝ $17.003/28/2025ABUSArbutus BiopharmaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/20/2025IMVTImmunovantGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/20/2025IMVTImmunovantBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $33.003/19/2025IMVTImmunovantHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$51.00 ➝ $51.003/18/2025MLTXMoonLake ImmunotherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$67.003/10/2025IMVTImmunovantGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/4/2025IMVTImmunovantCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/3/2025IMVTImmunovantJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$20.003/2/2025IMVTImmunovantJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMixed ➝ Mixed(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.17M102.86N/AN/A$0.63 per share5.26HCMHUTCHMED$630.20M3.86$0.57 per share24.51$4.27 per share3.27IMVTImmunovantN/AN/AN/AN/A$2.08 per shareN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$8.15 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$72.85M-$0.38N/AN/AN/A-1,137.65%-68.18%-51.55%5/15/2025 (Estimated)HCMHUTCHMED$100.78MN/A0.009.56N/AN/AN/AN/A7/29/2025 (Estimated)IMVTImmunovant-$259.34M-$2.62N/AN/AN/AN/A-77.94%-69.82%6/4/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$36.01M-$1.89N/AN/AN/AN/A-15.54%-15.09%5/13/2025 (Estimated)Latest ABUS, MLTX, HCM, and IMVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/4/2025Q4 2025IMVTImmunovant-$0.72N/AN/AN/AN/AN/A5/15/2025Q1 2025ABUSArbutus Biopharma-$0.09N/AN/AN/A$2.54 millionN/A5/13/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.76N/AN/AN/AN/AN/A3/27/2025Q4 2024ABUSArbutus Biopharma-$0.08-$0.07+$0.01-$0.07$2.20 million$1.57 million2/26/2025Q4 2024MLTXMoonLake Immunotherapeutics-$0.63-$0.72-$0.09-$0.72N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A7.027.02HCMHUTCHMED0.072.812.68IMVTImmunovantN/A6.046.04MLTXMoonLake ImmunotherapeuticsN/A25.5125.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%HCMHUTCHMED8.82%IMVTImmunovant47.08%MLTXMoonLake Immunotherapeutics93.85%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%HCMHUTCHMED3.60%IMVTImmunovant5.90%MLTXMoonLake Immunotherapeutics12.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.48 million181.91 millionOptionableHCMHUTCHMED1,760174.32 million168.04 millionNot OptionableIMVTImmunovant120169.86 million159.84 millionOptionableMLTXMoonLake Immunotherapeutics264.01 million56.22 millionOptionableABUS, MLTX, HCM, and IMVT HeadlinesRecent News About These CompaniesGranahan Investment Management LLC Sells 36,196 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)May 12 at 6:35 AM | marketbeat.comBalyasny Asset Management L.P. Reduces Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 11 at 5:31 AM | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Acquired by Fred Alger Management LLCMay 10 at 8:33 AM | marketbeat.comCaption Management LLC Invests $670,000 in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 9 at 6:18 AM | marketbeat.comThe Manufacturers Life Insurance Company Buys 24,576 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)May 9 at 4:23 AM | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Position Cut by BVF Inc. ILMay 6, 2025 | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)May 2, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Strong Trading Volume - Should You Buy?May 1, 2025 | marketbeat.comMoonLake Immunotherapeutics (MLTX) Projected to Post Quarterly Earnings on TuesdayMay 1, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by Adage Capital Partners GP L.L.C.May 1, 2025 | marketbeat.comBTIG Boosts Price Target for MoonLake Immunotherapeutics (MLTX) to $85 | MLTX Stock NewsApril 30, 2025 | gurufocus.comMoonLake Immunotherapeutics: Promising Developments and Financial Strength Justify Buy RatingApril 29, 2025 | tipranks.comMoonLake Immunotherapeutics: Promising Clinical Trials and Market Potential Drive Buy RatingApril 29, 2025 | tipranks.comMoonLake Immunotherapeutics: Promising Developments and Strategic Positioning Justify Buy RatingApril 29, 2025 | tipranks.comVoya Investment Management LLC Purchases 39,657 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)April 29, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stake Increased by Price T Rowe Associates Inc. MDApril 29, 2025 | marketbeat.comMoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29April 26, 2025 | finanznachrichten.deMoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 | MLTX Stock NewsApril 25, 2025 | gurufocus.comMoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29April 25, 2025 | gurufocus.comMoonLake Immunotherapeutics Announces Capital Markets Day to Highlight Financial and Clinical ...April 25, 2025 | gurufocus.comMoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29April 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABUS, MLTX, HCM, and IMVT Company DescriptionsArbutus Biopharma NASDAQ:ABUS$3.32 +0.09 (+2.63%) As of 01:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.HUTCHMED NASDAQ:HCM$13.96 -0.25 (-1.79%) As of 01:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Immunovant NASDAQ:IMVT$14.53 +0.51 (+3.62%) As of 01:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.MoonLake Immunotherapeutics NASDAQ:MLTX$40.65 +2.18 (+5.67%) As of 01:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
